OncoMed Pharmaceuticals Company Profile (NASDAQ:OMED)

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals logoOncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company's product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company's Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company's Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OMED
  • CUSIP:
Key Metrics:
  • Previous Close: $11.25
  • 50 Day Moving Average: $11.05
  • 200 Day Moving Average: $11.70
  • 52-Week Range: $8.42 - $23.98
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.57
  • P/E Growth: 0.00
  • Market Cap: $350.57M
  • Outstanding Shares: 30,671,000
  • Beta: 2.88
Profitability:
  • Net Margins: -424.46%
  • Return on Equity: -1,307.23%
  • Return on Assets: -17.96%
Debt:
  • Current Ratio: 4.10%
  • Quick Ratio: 4.10%
Additional Links:
Companies Related to OncoMed Pharmaceuticals:

Analyst Ratings

Consensus Ratings for OncoMed Pharmaceuticals (NASDAQ:OMED) (?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $20.43 (78.73% upside)

Analysts' Ratings History for OncoMed Pharmaceuticals (NASDAQ:OMED)
Show:
DateFirmActionRatingPrice TargetDetails
9/22/2016HC WainwrightInitiated CoverageBuy$20.00View Rating Details
8/10/2016Jefferies GroupBoost Price TargetBuy$15.00 -> $16.00View Rating Details
7/14/2016Cantor FitzgeraldReiterated RatingBuy$16.00View Rating Details
6/1/2016MizuhoLower Price TargetNeutral$45.00 -> $40.00View Rating Details
5/5/2016Leerink SwannBoost Price TargetMarket Perform$11.00 -> $13.00View Rating Details
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$20.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$21.00 -> $18.00View Rating Details
12/3/2015Wells Fargo & Co.Initiated CoverageOutperformView Rating Details
6/2/2015Piper Jaffray Cos.Set Price TargetBuy$43.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for OncoMed Pharmaceuticals (NASDAQ:OMED)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/9/2016Q216($0.81)($0.91)$8.09 million$6.67 millionViewN/AView Earnings Details
5/5/2016Q1($0.73)($0.90)$8.28 million$6.40 millionViewN/AView Earnings Details
3/10/2016Q4$0.41$1.50$44.55 million$6.80 millionViewListenView Earnings Details
11/5/2015Q315($0.80)($0.81)$5.84 million$4.70 millionViewListenView Earnings Details
8/10/2015Q215($0.49)($0.72)$13.78 million$4.70 millionViewListenView Earnings Details
5/7/2015Q115($0.35)($0.49)$15.35 million$9.70 millionViewN/AView Earnings Details
3/12/2015Q414($0.27)($0.50)$11.92 million$8.51 millionViewN/AView Earnings Details
11/4/2014($0.30)($0.18)ViewN/AView Earnings Details
8/7/2014Q214($0.03)($0.53)$21.28 million$6.00 millionViewN/AView Earnings Details
5/8/2014Q114($0.13)($0.47)ViewN/AView Earnings Details
3/18/2014Q4 13$0.15($0.15)$20.37 million$19.00 millionViewN/AView Earnings Details
11/12/2013Q3$0.12($0.15)ViewN/AView Earnings Details
9/3/2013Q2 2013($0.02)($0.83)$8.31 million$2.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for OncoMed Pharmaceuticals (NASDAQ:OMED)
Current Year EPS Consensus Estimate: $-3.34 EPS
Next Year EPS Consensus Estimate: $-1.51 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.94)$1.15($0.21)
Q2 20161($0.87)($0.87)($0.87)
Q3 20164($0.75)($0.58)($0.68)
Q4 20162($0.74)($0.74)($0.74)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for OncoMed Pharmaceuticals (NASDAQ:OMED)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for OncoMed Pharmaceuticals (NASDAQ:OMED)
Insider Ownership Percentage: 41.25%
Institutional Ownership Percentage: 30.66%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/11/2016Jakob DupontSVPSell2,500$20.01$50,025.00View SEC Filing  
1/7/2016Alicia J. HagerVPSell1,623$22.28$36,160.44View SEC Filing  
1/7/2016John A. LewickiEVPSell2,162$22.28$48,169.36View SEC Filing  
1/6/2016Paul J. HastingsCEOSell2,412$22.28$53,739.36View SEC Filing  
11/27/2015Alicia J. HagerVPSell1,800$23.14$41,652.00View SEC Filing  
10/27/2015Alicia J. HagerVPSell5,400$21.00$113,400.00View SEC Filing  
10/26/2015Austin GurneyInsiderSell14,000$20.00$280,000.00View SEC Filing  
10/26/2015Jakob DupontSVPSell5,000$20.00$100,000.00View SEC Filing  
9/30/2015Jack W. LasersohnDirectorBuy11,210$16.01$179,472.10View SEC Filing  
9/29/2015Jack W. LasersohnDirectorBuy3,140$14.15$44,431.00View SEC Filing  
9/28/2015Jack W. LasersohnDirectorBuy10,000$14.74$147,400.00View SEC Filing  
7/10/2015Jakob DupontSVPSell2,500$20.13$50,325.00View SEC Filing  
7/6/2015Jakob DupontSVPSell2,500$21.22$53,050.00View SEC Filing  
6/29/2015Alicia J HagerVPSell1,800$22.67$40,806.00View SEC Filing  
6/22/2015Timothy HoeySVPSell5,000$26.07$130,350.00View SEC Filing  
6/16/2015John A LewickiEVPSell17,000$25.07$426,190.00View SEC Filing  
6/15/2015John A LewickiEVPSell8,500$24.92$211,820.00View SEC Filing  
5/27/2015Alicia J HagerVPSell1,800$23.07$41,526.00View SEC Filing  
5/18/2015Austin GurneyInsiderSell4,000$22.48$89,920.00View SEC Filing  
4/27/2015Alicia J HagerVPSell1,800$25.65$46,170.00View SEC Filing  
4/27/2015Timothy HoeySVPSell6,887$25.65$176,651.55View SEC Filing  
4/17/2015Austin GurneyInsiderSell4,000$25.51$102,040.00View SEC Filing  
4/10/2015Jakob DupontSVPSell1,500$26.51$39,765.00View SEC Filing  
4/2/2015John A LewickiEVPSell17,000$25.28$429,760.00View SEC Filing  
3/20/2015Sunil PatelInsiderSell18,000$27.76$499,680.00View SEC Filing  
3/17/2015Austin GurneyInsiderSell4,000$27.37$109,480.00View SEC Filing  
2/5/2015Timothy HoeySVPSell7,500$22.83$171,225.00View SEC Filing  
2/2/2015John A LewickiEVPSell4,000$22.49$89,960.00View SEC Filing  
1/20/2015Austin GurneyInsiderSell4,000$22.87$91,480.00View SEC Filing  
1/12/2015Jakob DupontSVPSell1,500$25.89$38,835.00View SEC Filing  
1/5/2015Jakob DupontSVPSell7,500$23.00$172,500.00View SEC Filing  
1/2/2015John A LewickiEVPSell4,000$22.10$88,400.00View SEC Filing  
12/31/2014Denise Pollard-KnightDirectorSell3,799$21.66$82,286.34View SEC Filing  
12/30/2014Denise Pollard-KnightDirectorSell17,607$21.63$380,839.41View SEC Filing  
12/18/2014Jonathan D RootDirectorSell13,052$21.05$274,744.60View SEC Filing  
12/17/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
12/10/2014Denise Pollard-KnightDirectorSell32,940$21.78$717,433.20View SEC Filing  
12/9/2014Denise Pollard-KnightDirectorSell23,273$21.78$506,885.94View SEC Filing  
12/8/2014Denise Pollard-KnightDirectorSell1,727$21.68$37,441.36View SEC Filing  
12/5/2014Denise Pollard-KnightDirectorSell25,000$21.60$540,000.00View SEC Filing  
12/1/2014John A LewickiEVPSell4,000$21.19$84,760.00View SEC Filing  
11/5/2014Timothy HoeySVPSell2,500$19.51$48,775.00View SEC Filing  
10/29/2014Paul J HastingsCEOSell16,769$21.99$368,750.31View SEC Filing  
10/2/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
10/2/2014John A LewickiEVPSell5,809$20.00$116,180.00View SEC Filing  
9/4/2014Jack W LasersohnDirectorBuy3,170$18.35$58,169.50View SEC Filing  
9/3/2014Jack W LasersohnDirectorBuy3,000$18.40$55,200.00View SEC Filing  
9/2/2014John A LewickiEVPSell2,191$20.01$43,841.91View SEC Filing  
8/22/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
8/21/2014Deepika PakianathanDirectorBuy80,203$18.98$1,522,252.94View SEC Filing  
8/15/2014Jack W LasersohnDirectorBuy1,045$17.00$17,765.00View SEC Filing  
8/5/2014Timothy HoeySVPSell2,500$21.66$54,150.00View SEC Filing  
8/1/2014John A LewickiEVPSell4,000$20.98$83,920.00View SEC Filing  
7/29/2014Paul J HastingsCEOSell16,770$22.11$370,784.70View SEC Filing  
7/23/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  
7/17/2014Austin GurneyInsiderSell4,000$20.46$81,840.00View SEC Filing  
7/1/2014John A LewickiEVPSell4,000$23.86$95,440.00View SEC Filing  
6/30/2014Denise Pollard-KnightDirectorSell11,485$23.59$270,931.15View SEC Filing  
6/26/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  
6/25/2014Denise Pollard-KnightDirectorSell3,252$23.56$76,617.12View SEC Filing  
6/24/2014Denise Pollard-KnightDirectorSell64,561$24.08$1,554,628.88View SEC Filing  
6/17/2014Austin GurneyInsiderSell4,000$24.99$99,960.00View SEC Filing  
6/16/2014John A LewickiEVPSell4,000$24.59$98,360.00View SEC Filing  
6/10/2014Presidio Management Group ViiiMajor ShareholderSell13,052$24.57$320,687.64View SEC Filing  
5/12/2014Presidio Management Group Viiimajor shareholderSell46,327$21.99$1,018,730.73View SEC Filing  
7/23/2013Denise Pollard-KnightDirectorBuy58,824$17.00$1,000,008.00View SEC Filing  
7/23/2013Presidio Management Group ViiiMajor ShareholderBuy158,823$17.00$2,699,991.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for OncoMed Pharmaceuticals (NASDAQ:OMED)
DateHeadline
capitalcube.com logoOncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : OMED-US : September 30, 2016 (NASDAQ:OMED)
www.capitalcube.com - September 30 at 11:50 AM
seekingalpha.com logoBuy Shares Of This Overlooked Biotech With Catalysts - Seeking Alpha (NASDAQ:OMED)
seekingalpha.com - September 29 at 6:32 PM
streetinsider.com logoOncoMed Pharma (OMED) to Present Interim Data for Wnt Inhibitors at ESMO - StreetInsider.com (NASDAQ:OMED)
www.streetinsider.com - September 29 at 6:32 PM
streetinsider.com logoOncoMed Pharma (OMED) to Present Interim Data for Wnt Inhibitors at ESMO (NASDAQ:OMED)
www.streetinsider.com - September 29 at 11:45 AM
finance.yahoo.com logoOncoMed to Present Clinical Data for Wnt Inhibitors at the ESMO 2016 Congress (NASDAQ:OMED)
finance.yahoo.com - September 29 at 11:45 AM
fidaily.com logoH.C. Wainwright Starts Coverage on OncoMed Pharmaceuticals, Inc. (OMED) By Announcing An Initial Rating Of “Buy” (NASDAQ:OMED)
www.fidaily.com - September 22 at 11:23 AM
finance.yahoo.com logoCoverage initiated on OncoMed Pharma by H.C. Wainwright (NASDAQ:OMED)
finance.yahoo.com - September 22 at 11:23 AM
capitalcube.com logoOncoMed Pharmaceuticals, Inc. – Value Analysis (NASDAQ:OMED) : September 21, 2016 (NASDAQ:OMED)
www.capitalcube.com - September 21 at 6:11 PM
News IconNotable Monday Option Activity: CSOD, OMED, ZIOP (NASDAQ:OMED)
www.stockoptionschannel.com - September 20 at 11:52 AM
capitalcube.com logoOncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : OMED-US : September 20, 2016 (NASDAQ:OMED)
www.capitalcube.com - September 20 at 11:52 AM
News IconStock Tracker: Earnings & Estimates for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Frisco Fastball (NASDAQ:OMED)
friscofastball.com - September 19 at 6:35 PM
4-traders.com logoOncomed Pharmaceuticals : Institutional Investors Sentiment Change (NASDAQ:OMED)
www.4-traders.com - September 19 at 11:04 AM
News IconHow Many Oncomed Pharmaceuticals Inc (NASDAQ:OMED)'s ... - Post News (NASDAQ:OMED)
www.kentuckypostnews.com - September 17 at 6:07 PM
News IconNew Market Report: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)
reports.pr-inside.com - September 15 at 10:03 AM
investornewswire.com logoCan Shares Of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Hit $26 - Investor Newswire (NASDAQ:OMED)
www.investornewswire.com - September 14 at 6:43 PM
capitalcube.com logoETF’s with exposure to OncoMed Pharmaceuticals, Inc. : September 9, 2016 (NASDAQ:OMED)
www.capitalcube.com - September 9 at 11:21 AM
News IconStock Struggling for the Quarter: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Post News (NASDAQ:OMED)
www.kentuckypostnews.com - September 4 at 10:41 AM
News IconOncoMed Pharmaceuticals, Inc Clinical Review, Industry Analysis, Market Size and Forecast 2016 – 2020 - Medgadget (blog) (NASDAQ:OMED)
www.medgadget.com - September 4 at 10:41 AM
News IconOncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic ... - EconoTimes (NASDAQ:OMED)
www.econotimes.com - September 2 at 6:30 PM
nasdaq.com logoOncoMed Management to Present at Two Upcoming Investment Conferences (NASDAQ:OMED)
www.nasdaq.com - September 2 at 11:27 AM
globenewswire.com logoOncoMed Pharmaceuticals Completes Enrollment of Phase 2 PINNACLE Clinical Trial of Tarextumab in Small Cell ... - GlobeNewswire (press release) (NASDAQ:OMED)
globenewswire.com - September 1 at 6:34 PM
finance.yahoo.com logoOncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic ... - Yahoo Finance (NASDAQ:OMED)
finance.yahoo.com - September 1 at 6:34 PM
News IconStock Down in Trading Session: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Post News (NASDAQ:OMED)
www.kentuckypostnews.com - September 1 at 9:45 AM
publicnow.com logoOncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer (NASDAQ:OMED)
www.publicnow.com - September 1 at 9:45 AM
reuters.com logoBRIEF-Oncomed Pharmaceuticals provides topline data from phase 2 trial on Tarextumab (NASDAQ:OMED)
www.reuters.com - August 30 at 9:55 AM
publicnow.com logoOncoMed Pharmaceuticals Completes Enrollment of Phase 2 PINNACLE Clinical Trial of Tarextumab in Small Cell Lung Cancer (NASDAQ:OMED)
www.publicnow.com - August 30 at 9:55 AM
reuters.com logoBRIEF-BVF Inc reports 4.9 pct passive stake in Oncomed Pharmaceuticals - SEC filing (NASDAQ:OMED)
www.reuters.com - August 27 at 10:54 AM
reuters.com logoBRIEF-BVF Inc reports 4.9 pct passive stake in Oncomed Pharmaceuticals - S... - Reuters (NASDAQ:OMED)
in.reuters.com - August 26 at 6:22 PM
nasdaq.com logoOncoMed Pharmaceuticals Announces Closing of Public Offering Including Exercise of Underwriters' Right to Purchase ... - Nasdaq (NASDAQ:OMED)
www.nasdaq.com - August 25 at 11:45 AM
reuters.com logoBRIEF-Gravity posts Q2 loss of $0.40 per ADS (NASDAQ:OMED)
www.reuters.com - August 24 at 9:42 AM
4-traders.com logoONCOMED PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) (NASDAQ:OMED)
www.4-traders.com - August 24 at 9:42 AM
News IconIs it Time to Buy OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED ... - Post News (NASDAQ:OMED)
www.kentuckypostnews.com - August 23 at 6:47 PM
biz.yahoo.com logoONCOMED PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and (NASDAQ:OMED)
biz.yahoo.com - August 23 at 6:47 PM
publicnow.com logoOncoMed Pharmaceuticals Announces Closing of Public Offering Including Exercise of Underwriters' Right to Purchase Additional Shares (NASDAQ:OMED)
www.publicnow.com - August 23 at 6:47 PM
News IconStock Tracking Lower for the Quarter: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Post News (NASDAQ:OMED)
www.kentuckypostnews.com - August 20 at 6:18 PM
investornewswire.com logoWill OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Hit $29 Price Target? - Investor Newswire (NASDAQ:OMED)
www.investornewswire.com - August 19 at 6:33 PM
News IconNVIDIA Corporation (NASDAQ:NVDA) & Oncomed Pharmaceuticals (NASDAQ:OMED) Stock's Buzzers - Money News (press release) (NASDAQ:OMED)
www.newsismoney.com - August 19 at 6:33 PM
globenewswire.com logoOncoMed Pharmaceuticals Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release) (NASDAQ:OMED)
globenewswire.com - August 19 at 6:33 PM
marketexclusive.com logoWhat To Look For In The Upcoming Oncomed Pharmaceuticals Inc (NASDAQ:OMED) Trial Data - Market Exclusive (NASDAQ:OMED)
marketexclusive.com - August 19 at 6:33 PM
News IconWhy Oncomed Pharmaceuticals Inc's Share Price (but Not Its Valuation) Plummeted Today - Madison.com (NASDAQ:OMED)
host.madison.com - August 19 at 6:33 PM
insidermonkey.com logoWhat To Look For In The Upcoming Oncomed Pharmaceuticals Inc (OMED) Trial Data (NASDAQ:OMED)
www.insidermonkey.com - August 18 at 6:48 PM
finance.yahoo.com logoONCOMED PHARMACEUTICALS INC Financials (NASDAQ:OMED)
finance.yahoo.com - August 18 at 6:48 PM
fool.com logoWhy Oncomed Pharmaceuticals Inc's Share Price (but Not Its Valuation) Plummeted Today (NASDAQ:OMED)
www.fool.com - August 18 at 6:48 PM
reuters.com logoBRIEF-OncoMed Pharmaceuticals prices public offering of common stock (NASDAQ:OMED)
www.reuters.com - August 18 at 9:41 AM
publicnow.com logoOncoMed Pharmaceuticals Announces Pricing of Public Offering of Common Stock (NASDAQ:OMED)
www.publicnow.com - August 18 at 9:41 AM
uk.finance.yahoo.com logoBUZZ-OncoMed Pharmaceuticals: Set to open at 3-mth low after equity raise (NASDAQ:OMED)
uk.finance.yahoo.com - August 18 at 9:41 AM
streetinsider.com logoOncoMed Pharma (OMED) Commences Common Stock Offering (NASDAQ:OMED)
www.streetinsider.com - August 17 at 6:53 PM
reuters.com logoBRIEF-Oncomed Pharmaceuticals announces proposed public offering of common stock (NASDAQ:OMED)
www.reuters.com - August 17 at 6:53 PM
marketexclusive.com logoWhat To Look For In The Upcoming Oncomed Pharmaceuticals Inc (NASDAQ:OMED) Trial Data (NASDAQ:OMED)
marketexclusive.com - August 17 at 6:53 PM
finance.yahoo.com logo4:08 pm OncoMed Pharma announces proposed public offering of common stock (NASDAQ:OMED)
finance.yahoo.com - August 17 at 6:53 PM

Social

OncoMed Pharmaceuticals (NASDAQ:OMED) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff